Thirty multidrug-resistant P.aeruginosa strains, isolated from clinical samples during 2011-2012, were investigated for the mechanisms' of resistance determination to quinolones. It is the first report in Bulgaria regarding the detection of point mutations in the quinolone resistance-determining regions of gyrA and parC as well as for the efflux pomp regulatory mexR genes by the Sanger sequencing method. Mutations, related to quinolone resistance were detected in codon 83 of gyr A gene, codons 87 and 136 of the parC and codons 126 and 44 of the mexR regulatory gene. Mutations in gyr A gene were found in all P.aeruginosa strains, resistant to ciprofloxacin.
INTRODUCTION
Pseudomonas aeruginosa is a non-fermenting Gram-negative microorganism which is a major dreaded cause of infection among hospitalized patients, usually with localized or systemic impairment of immune defence. It is a common cause of hospital-acquired infections like pneumonia, urinary-tract infections, wound infections, respiratory tract infections, bloodstream infections, especially in the units with high risk for infection development (1, 2) . According to our data for 2011, P. aeruginosa occupies the 5th place with 7.2% among the first 10 most frequently isolated microorganisms in MMA and with 17.1% isolation in ICU, as well (3) . Resistance to currently available antibiotics in nosocomial Gram-negative isolate, especially in multidrug-resistant P. aeruginosa strains has become a significant problem over the past decade (4) . Due to the significant intrinsically expressed resistance of the P. aeruginosa strains to the majority of antimicrobial compounds, the antibiotic classes that remain active include _____________________________ fluoroquinolones,aminoglycosides, carbapenems and colistin (1) . But the problem, which is very important for the treatment of infections, caused by these microorganisms, is the resistance development to quinolones in the last years. The main mechanisms of resistance are mutations in the target genes, those encoding DNA gyrase (gyrA) and topoisomerase IV (parC) (2, 5, 6) and in regulatory genes for drug efflux pumps (7) .
The aim of this study is to examine the occurrence of mutations related to fluoroquinolones resistance (gyrA and parC genes) and regulatory genes for drug efflux pumps -mexR, using the Sanger sequencing technique of 30 clinical strains of P. aeruginosa, isolated at Military Medical Academy in Sofia, Bulgaria.
MATERIALS AND METHODS

Clinical isolates
Thirty multidrug-resistant P. aeruginosa strains, isolated during 2011-2012 with a resistant profile to fluoroquinolones, were investigated. The isolates have been recovered from different clinical samples in patients who were treated in Intensive care units (ICU), Anesthesiology and Resuscitation clinic (ARC), Hepato-pancreatic surgery (HPS), Traumatology, and in ambulatory patients at the Military Medical Academy, Sofia (Table 1) . The identification and antimicrobial susceptibility profiling analysis of the isolates were performed by Vitek 2 (bioMérieux, France) and conventional methods (8) and the resistance' results were interpreted according to the CLSI guideline (9) 
ARC -Anestesiology and Resuscitation Clinic; ICU -Intensive Care Unit; HPS -Hepato -pancreatic surgery; Traum. -Traumatology; Amb. -Ambulatory
Tzp -Piperacillin/Tazobactam; caz -Ceftazidime; fep -Cefepime; scf -Cefoperazon/Sulbactam; memmeropenem; amk -Amikacin; gen -Gentamycin; tbm -Tobramycin; cip -Ciprofloxacin; lvf -Levofloxacin.
DNA Extraction
The DNA of all isolates of P. aeruginosa was extracted using commercial kit E.Z.N.A. Bacterial DNA kit (10) according to the manufacturer's instructions and were used as template for PCR reactions.
Multiplex PCR
Мultiplex PCR reaction was set up using specific primers for genes for fluoroquuinolone resistance (gyrA, parC) in P. aeruginosa and regulatory gene (mexR). For amplification of target genes was used Mastermix 2,0X VWR Red Taq DNA Polymerase with final concentration of MgCl 2 -1,5mM (VWR GmbH International), specific primers from published data (7) 
Sanger sequencing reaction
Primers and free nucleotides from multiplex PCR reaction were removed using E.Z.N.A. ® Cycle Pure kit (Q-spin) (Omega Bio-tek, USA) according to the manufacturer's instructions (Omega Bio-tek) The purified PCR products were directly sequenced by dideoxynucleotides using capillary electrophoresis system GeXP Genetic analysis system (Beckman Coulter, USA). Cycle sequencing reaction was performed using GenomeLab™ DTCS Quick Start Kit (Beckman Coulter, USA) according to the manufacturer's instructions (11) . This reaction was set up at 20 µl final volume. Amplification of the target regions was performed in 30 cycles as follow: 96 о С for 20 sec, 50 о С for 20 sec and at 60 о С for 4 min. The PCR products were purified using ethanol precipitation and were resuspended in SLS buffer (Beckman Coulter, USA) and loaded on GeXP Genetic analysis system (Beckman Coulter, USA). All sequenced results were analyzed using Genome Lab GeXP software v.10.2. The sequences of the quinoloneresistance determining regions of gyrA and parC and the amplified region of mexR were compared with those from the corresponding quinolone-susceptible strain (PAO1) and the sequences present in the GenBank databases. GenBank accession numbers for the nucleotide sequences of gyrA, parC and mexR genes are L29417, D89652, U23763, and X65646, respectively.
RESULTS AND DISCUSSION
Multidrug-resistant (MDR bacterial infections are usually associated with big hospital complexes, like MMA in Sofia. It is a community hospital with 800 beds. The hospital is a one of the national centers for trauma, respiratory diseases, liver transplantation, patients' treatment, etc, with several surgery units and two ICUs / ICU and Anesthesiology and Resuscitation clinic (ARC). Antibiotic stewardship includes all groups of antibiotics together with carbapenems, quionolones, third and fourth generations of cephalosporins.
Thirty MDR P. aeruginosa strains (24 are resistant to ciprofloxacin with MIC ≥ 4 mg/l), isolated from different specimens at MMA, were investigated for the occurrence of mutations related to their resistance to quinolones.
Fragments of gyrA, parC and mexR genes were amplified using multiplex PCR and the efficacy of the amplification was estimated by gel electrophoresis. All fragments amplified adequately (Figure 1) . The PCR products were after examined for detection of point mutations in the quinolone resistance-determining regions of gyrA and parC as well as for the efflux pomp regulatory mexR genes by the Sanger sequencing method on GeXP Genetic Analysis System (Beckman Coulter, USA). Mutations in all 24 fluoroquinolone-resistant strains occurred in codon 83 (Thr to Ile) and no mutation accured in codon 87 of the gyrA gene ( Figure  2 ). Mutations in codons 87 (in 13 quinolone resistant strains) and 136 (in 3 quinolone resistant strains) were found in parC (Figure 3) . A mutation related to fluoroquinolone resistance in codon 126 of the mexR regulatory gene, changing amino acid Val to Glu, was detected ( Figure 4 ) and mutation in one strain in codon 44, changing amino acid Lys to Met was registered (Table 2) . Non sence mutations in gyrA: codon 68 (Arg) -in 12 strains; codon 103 (Val) -in 7 strains; codon 118 (Ala) -in 7 strains; codon 132 (His) -in 13 strains; codon 136 (Ala) -in 7 strains have been observed. As a reference sequence were used sequences of genes gyrA, parC and MexR from P.aeruginosa PAO1. Alignment of sequences was performed using Genome Lab GeXP software v.10.2. (Figures 2, 3, 4 (13, 14) . No mutations were found in par C in the study done by Gorgani, N. et al., 2009 (7) . No data were found in the literature regarding to a mutation in codon 136 and more studies are needed to determine whether this mutation is related to the resistance. On this background (our data together with these, obtained by other investigators) it can be considered, that gyrA mutations are the major mechanism of resistance to fluoroquinolones for clinical strains of P. aeruginosa and that additional mutations in parC could lead to a higher level of quinolone resistance (13) . A mutation, detected in the codon 126 of mexR regulatory gene (changing amino acid Val to Glu), probably lead to the hyper expression of the efflux pump MexABOprM (14, 15) . It was assumed, that a mexR mutation alone may not change the susceptibility of the bacteria but causes resistance when it cooccurs with a mutation on the gyrA gene (7).
In conclusion, this is the first report from Bulgaria, which confirms the results regarding the mechanisms of resistance to quinolones in clinical P. aeruginosa strains. The major mechanism of resistance of this bacterium to fluoroquinolones is the modification in gyrA gene supplemented by possible changes in parC and mexR regions. The results, obtained by us on MDR P. aeruginosa, show that the same mutations found in strains from other nationalities are associated with the fluoroquinolone resistance. This suggests that the same mechanisms of fluoroquinolone resistance play an important role in MDR isolates from Bulgaria.
